CSI Market
Sign In | Register

Ginkgo Bioworks Holdings Inc (DNA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access DNA quarterly Cash Flow →
A period-by-period view of cash flow from Ginkgo Bioworks Holdings Inc to Dec 31 2021 helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-312.76
Depreciation & amortization58.99
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation81.55
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Net Gain From Investments Held In Trust Account-
Non Cash Equity Consideration-
Changes In Fair Value Of Loans Receivable5.69
Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High-4.23
Deconsolidation Gain Or Loss Amount-
Operating Lease Expense-
Finance Lease Right Of Use Asset Amortization-
Gain Loss On Investments And Income Loss From Equity Method Investments-
Non Cash Customer Consideration-
Operating Lease Right Of Use Asset Amortization Expense30.08
Noncash In Process Research And Development-
Increase Decrease Right Of Use Assets-
Increase Decrease In Operating Lease Liability-27.93
Income taxes-1.36
Gain (Loss) on Investments16.41
Accounts Receivable8.90
Increase (Decrease) in Accounts Payable-2.99
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-5.25
Other Working Capital11.76
Other Noncash Income (Expense)2.06
Other net0.00
Payments for (Proceeds from) Other Operating Activities-31.97
Discontinued operations0.00
Net Cash flow from Operating Activities-171.06
Investing Activities
Capital Expenditures-7.67
Sale of Capital Items0.57
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities185.38
Payments to Acquire Available-for-sale Securities, Debt-418.63
Real Estate Investments0.00
Issuance Of Loan Receivable-
Proceedsfromloanreceivables-
Purchase Of Non Marketable Equity Securities-
Business Acquisitions Purchase Price Allocation Year Of Acquisition Net Effect On Income-
Payments To Acquire Equity Securities Fv Ni-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.05
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-240.29
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock18.13
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment Of Underwriters Discount-
Repayment Of Advances Received From Sponsor-
Repayment Of Advances Received From Promissory Note-
Proceeds From Reverse Recapitalization Net Of Redemption And Offering Costs-
Principal Payment On Capital Lease Obligations-
Finance Lease Principal Payments-0.35
Purchases Of Equipment Through Capital Leases-
Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses-
Deferred Offering Costs Included In Accounts Payable And Accrued Expenses-
Equity Received In Related Parties-
Purchase Of Non Cash Marketable Equity Securities-
Principal Payments On Capital Leases And Lease Financing Obligation-
Proceeds From Lease Financing Obligation-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities17.78
Effect of exchange rate on cash flow0.20
Discontinued operations0.00
Free Cash Flow-178.15
Total Cash Flow-393.37
4 historic quarters locked

Sign in to unlock the full Ginkgo Bioworks Holdings Inc cash flow history.

Sign In Create Free Account

About Ginkgo Bioworks Holdings Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: dna-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-012346

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License